BioMarin Initiates Phase 1 Trial for BMN-111; AstraZeneca Announces First Direct-to-Patient Program Print E-mail
By Staff and Wire Reports   
Thursday, 16 February 2012 19:15
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 16, 2012.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN)
announced the initiation of a Phase 1 study in healthy volunteers for BMN-111, an analog of C-type Natriuretic Peptide, for the treatment of achondroplasia. The company expects to report results from this trial in the third quarter of 2012.

=====

AstraZeneca (NYSE: AZN)
announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.



Also Thursday:



Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced its financial results for the fourth quarter and full year ended December 31, 2011.

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)
, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced its Annual Analyst and Investor Day will take place from 10 am to 1 pm ET on Tuesday, March 27th in New York.

AstraZeneca (NYSE: AZN)
today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
today announced financial results for the fourth quarter and full year ended December 31, 2011.

Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition to its SensiFAST family real-time PCR products.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX)
(the “Company”), a biopharmaceutical development company, announced today it has entered into definitive agreements with healthcare-focused U.S. institutional investors to place an aggregate of approximately 5,245,000 American Depositary Shares ("ADSs"), at a purchase price of $2.86 per ADS, and warrants to purchase up to 2,622,500 additional ADSs at an exercise price of $3.57 per ADS.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
, announced today that the company has entered into a privately-negotiated securities exchange agreement with a holder of BioSante’s 3.125% convertible senior notes due May 1, 2013.

Biovest International, Inc. (OTCQB: BVTI)
, a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), today announced that Biovest is scheduled to present at 19th International Molecular Med Tri-Con Cancer Biologics Conference to be held February 19–23 at the Moscone Convention Center in San Francisco.

Callidus Software Inc. (NASDAQ: CALD)
, the leader in sales effectiveness and cloud computing, announced today that MicroPact, a leading developer of advanced data tracking and business process management software, has selected the CallidusCloud™ Sales Enablement platform to drive the effectiveness of its global sales organization.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of Alison Lawton to its Board of Directors.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has received CE Mark in Europe for its EDWARDS INTUITY Valve System for use in patients undergoing surgical aortic valve replacement (AVR).

GenMark Diagnostics, Inc. (NASDAQ: GNMK) announced that, effective February 13, 2012, Dr. Jorge Garces has joined GenMark as Senior Vice President, Research and Development.

ICON (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the full year and fourth quarter ended December 31, 2011.

Progressive Care, Inc. (OTCBB: RXMD) and its subsidiary PharmCo, LLC, a provider of prescription pharmaceuticals, specializing in anti-viral patient management, long term care and home medical equipment, announced today that former Florida Department of Health Program Manager Chrystal McDonald has joined the Company's Board of Advisors to spearhead PharmCo's newly formed HIV/AIDS Action Committee.

SunLink Health Systems, Inc. (NYSE Amex Equities: SSY) today announced a loss from continuing operations for its second fiscal quarter ended December 31, 2011 of $1,586,000, or a loss of $0.17 per fully diluted share, compared to a loss from continuing operations of $2,100,000, or a loss of $0.26 per fully diluted share for the quarter ended December 31, 2010.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be presenting at the following upcoming investor conferences:  Citi 2012 Global Healthcare Conference in New York, Monday, February 27 at 10:00 a.m. (ET).



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter